As 2025 is coming to an end, we at ArgusEye are proud to reflect on a year of continued growth, exciting milestones, and strengthened partnerships. From expanding our team and customer base to launching new initiatives that enhance connectivity and access to information, this year has set the stage for even greater achievements in 2026.
A Fresh Digital Presence
This year we unveiled our new website and domain, featuring a modern design, improved navigation, and expanded content to provide the biopharmaceutical industry with easier access to information about our new technology and solutions.
Alongside this, we sent our first company newsletter, a quarterly digest of news, key updates, and insights to keep our customers, partners and stakeholders informed about the latest developments at ArgusEye.
Team Expansion and Leadership
Our team expanded by 56% in 2025, bringing additional internal expertise to software, hardware, production, and sales and marketing. This growth reflects our commitment to strengthening our capabilities and serving our customers with excellence.
This year we also welcomed Torben Jørgensen as our new Chairman of the Board. With extensive experience in the biopharmaceutical and life science industries, Torben brings strategic insights and financial acumen that has, and will continue to guide ArgusEye through the next phases of growth.
Knowledge-Sharing and Industry Engagement
We launched a webinar series, giving our audience new opportunities to engage with our team and discover the latest advancements in biopharmaceutical sensing technologies. The webinars were met with positive feedback, and all recordings are now available on-demand via our website, ensuring accessibility for all interested parties.
Our presence in the industry continued to grow through participation in leading conferences, including BioProcess International in Hamburg, Bioprocessing Summit in Boston, and the Integrated Continuous Biomanufacturing Conference VII in Dubrovnik. At these events, we showcased our Auga™ platform through booths, presentations, and posters, further establishing ArgusEye as a key player in the biopharmaceutical field.
We also attended Ny Teknik’s Unicorn Reunion in Stockholm, a gathering for all alumni companies from the prestigious 33-Listan. ArgusEye has proudly been featured on the list for three consecutive years, earning “Gold Company” status and alumni recognition in 2024. At the reunion this year, we engaged in intriguing discussions that offered valuable insights and perspectives on industry trends.
Recognition and Collaboration
During the last quarter of 2025, ArgusEye was honored with an Industrial PhD grant from the Swedish Foundation for Strategic Research (SSF), solidifying our ongoing collaboration with KTH. This partnership, along with collaborations with Lund University on multi-column chromatography control, demonstrates our commitment to driving scientific progress and innovation. Additionally, we expanded commercial collaborations with top biopharma companies, broadening our impact across the industry.
Expansion of Our Customer Base
This year, we continued to grow our customer base, partnering with some of the world’s largest pharmaceutical companies. These partnerships underscore the trust in ArgusEye’s technology and solutions, inspiring us to continue raising the bar in biopharmaceutical sensing.
Looking Ahead to 2026
Reflecting on the progress we’ve made this past year, we are confident in the strong foundation we have built and excited for what lies ahead.
Over the past year, we focused on setting the right foundations, developing the routines, tools, and structures that allow us to scale confidently. Looking ahead to 2026, we’re excited to carry this momentum forward, accelerate our progress, and make the most of the opportunities coming our way.
The upcoming year promises several highly anticipated launches, including our second portfolio product, and new solutions for aggregate detection and a broader dynamic range. To support these innovations, our team will continue to grow, enabling us to serve an expanding global client base.
As we move into 2026, we remain focused on innovation, collaboration, and delivering solutions that advance the biopharmaceutical industry.
Stay Tuned–Exciting News Ahead
The upcoming launch of our on-line system is just around the corner, and we can’t wait to share more details soon. Stay connected for more information shortly.
Subscribe to our newsletter and receive the latest insights, company updates, and announcements directly in your inbox.
Follow us on LinkedIn where we regularly share updates and company news.
Let's Connect
Do you have any questions, or would you like to connect with our team? Contact us using this form and we’ll get back to you shortly.
